Ventas, Inc (VTR) Fair Value & Analysis
Real Estate · US · Market cap $42.1B
Ventas, Inc
VTR · US
Fair value as of: Jul 27, 2026
From 16 valuation models · updated 14 days ago
Share price +1.0% over the past month.
Below-average quality, and screening another 84% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($15.36). The favourable scenario is already priced in.
- Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts.
- As a real-estate business, asset- and dividend-based methods carry more weight here than a standard DCF.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 27, 2026.
How to read this chart
60‑month range $32.05 – $100.53 · fair‑value band $10.95 – $15.36 · the $93.36 price screens above the $15.36 fair value. Dashed = 300-day average. As of Jul 27, 2026.
Analysis
Ventas, Inc (VTR) currently trades at $93.36, while our model-based Fair Value estimate is $15.36, implying the stock looks roughly 83.6% overvalued today. The Quality Score stands at 41/100 (below-average quality), in the Real Estate sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Ventas, Inc generated revenue of $6.1B at a net margin of 4.3%. Revenue grew 21.9% year over year. It earns a return on equity of 2.1%. Net debt stands at $12.5B. Fundamentals as of Jul 27, 2026
Our scenario range runs from $10.95 (bear case) to $15.36 (bull case); at $93.36, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 54% above its 52-week low, currently above its 200-day average. For context, the median of 10 Real Estate peers we cover trades at -48% fair-value upside, at -84%, VTR screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 16 models by family
Widest divergence: DCF Models ($34.91) versus Growth DCF ($8.63). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 27, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 43 · Market factors (momentum, volatility) 78
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Ventas, Inc. is a leading S&P 500 real estate investment trust enabling exceptional environments that benefit a large and growing aging population. With approximately 1,400 properties in North America and the United Kingdom, Ventas occupies an essential role in the longevity economy.
Full company description
Ventas, Inc. is a leading S&P 500 real estate investment trust enabling exceptional environments that benefit a large and growing aging population. With approximately 1,400 properties in North America and the United Kingdom, Ventas occupies an essential role in the longevity economy. The Company's growth is fueled by its more than 850 senior housing communities, which provide valuable services to residents and enable them to thrive in supported environments. Ventas aims to deliver outsized performance by leveraging its operational expertise, data-driven insights from its Ventas OI platform, extensive relationships and strong financial position. The Ventas portfolio also includes outpatient medical buildings, research centers and healthcare facilities. Ventas's seasoned team of talented professionals shares a commitment to excellence, integrity and a common purpose of helping people live longer, healthier, happier lives. Ventas, Inc. was incorporated in 1983 and is based in Chicago, United States.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Ventas, Inc reported revenue of $5.8B in FY2025 versus $3.8B in FY2021, a compound +11.1%/yr. Reported net income was $251M in FY2025, compounding +50.5%/yr from FY2021.
VTR screens 84% overvalued. Compare with Welltower Inc →
Recent news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Ventas Q2 Earnings Call Highlights
- Ventas Inc (VTR) (Q2 2026) Earnings Call Highlights: Record NOI Growth and Raised Guidance ...
- Ventas Q2 FFO & Revenues Beat Estimates on Strong SHOP Growth
- Ventas (VTR) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Peer Group
REIT - Healthcare Facilities · 28 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs REIT - Healthcare Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 46/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more REIT - Healthcare Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 27, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Welltower Inc WELL | $231.59 | $42.21 | -82% |
| Omega Healthcare Investors, Inc OHI | $51.72 | $33.69 | -35% |
| Healthpeak Properties, Inc DOC | $22.27 | $7.02 | -68% |
| American Healthcare REIT, Inc AHR | $56.38 | $11.04 | -80% |
| CareTrust REIT, Inc CTRE | $43.25 | $23.07 | -47% |
| Healthcare Realty Trust Incorporated HR | $21.40 | $20.60 | -4% |
| Aedifica NV AED | €69.85 | €36.17 | -48% |
| Chartwell Retirement Residences CSHUN | C$22.81 | C$3.52 | -85% |
| Sabra Health Care REIT, Inc SBRA | $22.36 | $10.49 | -53% |
| National Health Investors, Inc NHI | $80.54 | $49.86 | -38% |
Compare Ventas, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Real Estate stocks →
Frequently asked questions
Is Ventas, Inc (VTR) overvalued or undervalued?
What is the fair value of VTR?
What is the quality score of VTR?
What is the revenue of Ventas, Inc (VTR)?
What is the net profit margin of VTR?
Does Ventas, Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Ventas, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.